Abstract
The document associated with this DOI has been withdrawn.
Highlights
Events of nonhealing-exposed bone in the maxillofacial region were initially reported in patients treated with intravenous (IV) bisphosphonates (BP).[1]
We report of a case of late medication-related osteonecrosis of the jaw (MRONJ) onset, 3 years after administration of ipilimumab
In the following years a warning followed for all BPs to be at risk for ONJ, which was renamed as bisphosphonate-related ONJ (BRONJ).[3]
Summary
Events of nonhealing-exposed bone in the maxillofacial region were initially reported in patients treated with intravenous (IV) bisphosphonates (BP).[1]. Novel chemotherapy agents, such as immunotherapy or targeted therapy are increasingly used in the clinical practice. Adopted for Metastatic Melanoma (MM) therapy, immunotherapy and targeted therapy agents are used in a wide and increasing variety of cancers, such as head & neck, urologic, gynecologic and pulmonary neoplasms, in regard to bone metastasis control. We investigated literature to understand a possible impact of such novel cancer therapies on MRONJ and report our experience in managing an unusual case of osteonecrosis onset 3 years after the administration of ipilimumab
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
